Givlaari lowers rate of porphyria attacks

Patients with acute hepatic porphyria treated with Givlaari experienced a lower rate of porphyria attacks, according to results of the ENVISION study.Givlaari (givosiran, Alnylam) is a GaINAc-conjugate RNAi therapeutic that targets aminolevulinic acid synase 1 (ALAS1) for the treatment of acute hepatic porphyrias (AHP).“Patients with AHP suffer through debilitating and potentially life-threatening attacks, and for some, chronic pain between attacks, resulting in a diminished quality of life and ability to function day-to-day,” Manisha Balwani, MD, MS, of the Icahn School ofRead More

Share on facebook
Share on twitter
Share on linkedin